Answers are grounded in this paper and cite their sources.
OBJECTIVES: Primary intestinal lymphangiectasia (PIL) is a rare congenital malformation causing protein-losing enteropathy. Given limited data on long-term dietary outcomes, this study describes clinical features, dietary response durability, and second-line therapies in an Italian pediatric cohort. METHODS: This multicenter retrospective study (2012-2025) analyzed children with PIL. Complete clinical remission required symptom resolution, normalized serum albumin, and intravenous albumin independence. Endoscopic and histological remissions were defined as the absence of macroscopic alterations and lymphatic vessel dilatation, respectively. RESULTS: Eighteen patients were included (median onset/diagnosis: 9 and 16 months, respectively). Key symptoms were ascites (82.4%), peripheral edema (76.5%), and lymphedema (64.7%); 94.1% showed profound hypoalbuminemia, hypoproteinemia, and hypogammaglobulinemia. Endoscopy revealed "snowflake" mucosa in 86.7%. Although all started a low-fat, high-protein medium-chain triglycerides diet, only 27.7% (5/18) achieved sustained complete remission on diet alone. Due to dietary failure, 55.6% (10/18) required second-line treatments (octreotide, sirolimus), with limited remission rates (1/4 and 2/7, respectively); one refractory child achieved remission with everolimus after sirolimus failure. At a median 5-year follow-up, endoscopic and histological remissions were reached in 54.5% (6/11) and 57.1% (4/7) of re-evaluated patients. CONCLUSIONS: PIL poses significant therapeutic challenges. Our findings show a loss of response to dietary management over time in a subset of patients, requiring tailored second-line pharmacological interventions whose management currently relies on limited clinical experiences in refractory cases.
No takes yet. Share an insight, caveat, or question.
Renzo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: